Health, Fitness & Food

In this article CI HUM Follow your favorite stocksCREATE FREE ACCOUNT Sopa Images | Lightrocket | Getty Images Shares of Cigna jumped Monday following reports that the health-care giant has scrapped its plans to buy rival Humana due to disagreements on price, putting an early end to what would have been one of the largest

In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released

It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna will

In this article VRTX CRSP Follow your favorite stocksCREATE FREE ACCOUNT The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after the discovery of CRISPR technology for editing human DNA, representing a significant scientific advancement.

President Joe Biden speaks about protecting Social Security, Medicare, and lowering prescription drug costs, during a visit to OB Johnson Park and Community Center, in Hallandale Beach, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new

In this article CRSP VRTX Follow your favorite stocksCREATE FREE ACCOUNT At age 19, Joe Tsogbe underwent his first hip replacement. In his 20s, he averaged about nine hospitalizations a year. By his 30s, that rose to more than a dozen.  All the result of sickle cell disease, an inherited blood disorder where a genetic

In this article CERE ABBV Follow your favorite stocksCREATE FREE ACCOUNT A sign stands outside a Abbvie facility in Cambridge, Massachusetts, May 20, 2021. Brian Snyder | Reuters AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion.  Under the terms of the deal, AbbVie will pay $45 per share

Noor Siddiqui, founder and CEO of Orchid, during the web summit for careers during Day 2 of the 2014 Web Summit in Dublin, Ireland, Nov. 5, 2014. Stephen McCarthy | Getty Images Reproductive technology startup Orchid on Tuesday announced a comprehensive new genetic test that may help many prospective parents across the U.S. breathe a

In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT The FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy. Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity

In this article CVS Follow your favorite stocksCREATE FREE ACCOUNT A person walks by a CVS pharmacy store in Manhattan, New York, U.S., November 15, 2021.  Andrew Kelly | Reuters CVS Health on Tuesday said it will revamp how it prices prescription drugs and scrap a complex model that typically sets how much pharmacies get

Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions

BRAZIL – 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images) Sopa Images | Lightrocket | Getty Images Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming

In this article PFE MRNA NVAX Follow your favorite stocksCREATE FREE ACCOUNT A sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | Reuters Three years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine.  Only 15.7% of U.S.

Tourists visit the bars and country music venues in the Lower Broadway entertainment district in Nashville, Tennessee, Sept. 1, 2019. Robert Alexander | Archive Photos | Getty Images On a flight from Fort Lauderdale, Florida, to Nashville, Tennessee, earlier this month, 36-year-old Robin Shah settled into his seat and prepared to crank out some work

In this article ABBV IMGN Follow your favorite stocksCREATE FREE ACCOUNT Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion.  Shares of ImmunoGen jumped

In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences.  The drugmaker on Friday said it will stop developing

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced

In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT CFOTO | Future Publishing | Getty Images Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study.  The drugmaker

In this article NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT A 0.25 mg injection pen of Novo Nordisk’s weight loss drug Wegovy is shown in this photo in Oslo, Norway, on Aug. 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and

Jim Cramer urged Humana (HUM) not to pursue a merger with rival health insurer Cigna (CI), questioning the merits of a potential business combination and the likelihood of it passing U.S. antitrust review. Cigna and Humana could reach an agreement on a stock-and-cash transaction by the end of the year, The Wall Street Journal reported